14- methyl- 20- oxa- 5,7,14,26- tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa- 1(25),2(26),3,5,8(27),9,11,16,21,23- decaene

01/01/2021 - "Thus, the dual inhibitory activity on both the CLL survival pathway and BCR signaling identifies TG02 as a unique compound for clinical development in CLL and possibly other B cell malignancies."
12/01/2020 - "Assignment of the cell cultures to a more malignant methylation class appeared to be more closely associated with TG02 sensitivity than assignment to a higher WHO grade of the primary tumors. "
01/01/2019 - "TG02 exhibits strong anti-tumor cell activity with EC50 concentrations in the nanomolar range. "
02/01/2012 - "In vivo, TG02 exhibits favorable pharmacokinetics after oral dosing in xenograft models and accumulates in tumor tissues, inducing an effective blockade of both CDK and STAT signaling. "
04/01/2020 - "In summary, these data suggest that type I IFN may be combined with TG02 to limit glioblastoma growth, but that the well characterized effects of IFN and TG02 on apoptotic signaling are dispensable for synergistic tumor growth inhibition. "

05/15/2013 - "Two models of multiple myeloma xenograft were utilized to study the in vivo action of TG02. "
05/15/2013 - "TG02 potently inhibited proliferation and survival of multiple myeloma cell lines, even under protective bone marrow niche conditions, and selectively induced apoptosis of primary patient-derived malignant plasma cells. "
05/15/2013 - "Utilizing different multiple myeloma cell lines we determined the effect of TG02 over viability by MTT assays. "
05/15/2013 - "TG02 is a promising new antimyeloma agent that is currently in phase I clinical trials in leukemia and multiple myeloma patients."
01/01/2016 - "Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma."

04/01/2020 - "In the present study, human glioma-initiating cell line models were used to explore whether IFN-β modulates the anti-glioma activity of TG02. "
04/01/2020 - "However, BCL2 did not protect from the synergistic effects of IFN and TG02 on glioma cell growth. "
04/01/2020 - "Pre-exposure to IFN-β sensitized human glioma models to a subsequent exposure to TG02. "
01/01/2019 - "TG02 is a highly potent apoptosis-inducing agent in glioma cells in vitro. "
01/01/2019 - "We studied the activity of TG02 in 9 human long-term glioma cell lines (LTC) and 5 glioma-initiating cell lines (GIC) using various cell death assays in vitro and in the LN-229 LTC and ZH-161 GIC models in vivo. "

04/01/2020 - "In summary, these data suggest that type I IFN may be combined with TG02 to limit glioblastoma growth, but that the well characterized effects of IFN and TG02 on apoptotic signaling are dispensable for synergistic tumor growth inhibition. "
01/01/2019 - "Caspase inhibition does not rescue TG02-treated cells and repetitive exposure fails to confer acquired resistance, supporting the clinical evaluation of TG02 in glioblastoma."
04/01/2020 - "Interferon-β sensitizes human glioblastoma cells to the cyclin-dependent kinase inhibitor, TG02."
04/01/2020 - "TG02 is a novel orally available cyclin-dependent kinase 9 inhibitor which induces glioma cell apoptosis without profound caspase activation, which is currently explored in early clinical trials in newly diagnosed and recurrent glioblastoma. "

02/01/2012 - "These data demonstrate that TG02 is active in various models of leukemia and provide a rationale for the ongoing clinical evaluation of TG02 in patients with advanced leukemias."
05/15/2013 - "TG02 is a promising new antimyeloma agent that is currently in phase I clinical trials in leukemia and multiple myeloma patients."
02/01/2012 - "TG02 induces tumor regression after oral dosing on both daily and intermittent schedules in a murine model of mutant-FLT3 leukemia (MV4-11) and prolongs survival in a disseminated AML model with wild-type FLT3 and JAK2 (HL-60). "
01/12/2012 - "26h (SB1317/TG02) was progressed into development in 2010 and is currently undergoing phase 1 clinical trials in advanced leukemias and multiple myeloma."